
Please try another search
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Benjamin J. Zeskind | 40 | 2008 | Co-Founder, President, CEO & Director |
Ann Elyse Berman | 72 | 2021 | Independent Chair |
Douglas A. Lauffenburger | - | - | Member of Scientific Advisory Board |
Tanios Bekaii-Saab | - | - | Member of Pancreatic Cancer Advisory Board |
Laurie Bartlett Keating | 70 | 2021 | Independent Director |
Peter Feinberg | 63 | 2021 | Director |
Thomas J. Schall | 65 | 2024 | Director |
Diana F. Hausman | 61 | 2022 | Independent Director |
Vincent Chung | - | 2024 | Member of Pancreatic Cancer Advisory Board |
Jordan D. Berlin | - | 2024 | Member of Pancreatic Cancer Advisory Board |
Robert J. Carpenter | 79 | 2008 | Co-Founder & Chair Emeritus |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review